Forest Laboratories LLC v. Amneal Pharmaceuticals LLC
1:15-cv-00756
Overview
Parties
Defendant
Par Pharmaceutical, Inc. Operating Company
Represented By
6 Attorneys ListedGould & Ratner LLP
222 N. LaSalle Street, Suite 800
Bayard, P.A.
Bayard, P.A., 600 N. King Street
ADDRESS EXPIRED / UNKNOWN
ADDRESS EXPIRED / UNKNOWN, (302) 655-5000
ADDRESS EXPIRED / UNKNOWN
ADDRESS EXPIRED / UNKNOWN, (302) 888-6800
Plaintiff
Forest Laboratories LLC Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Forest Laboratories Holdings Ltd. NPE (Patent Assertion Entity)
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Allergan USA, Inc. Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Counter Claimant
Amneal Pharmaceuticals LLC Operating Company
Represented By
7 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Amneal Pharmaceuticals of New York LLC Operating Company
Represented By
7 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Counter Defendant
Adamas Pharmaceuticals Inc. Operating Company
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 10 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 8,039,009 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2012000431 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2013001259 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2013031046 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2014021365 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2015014842 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2015025803 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,660,868 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2020026868 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 58,124,204 P | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8039009
Modified release formulations of memantine oral dosage forms
|
Filed: 2005-06-16
Issued: 2011-10-18
|
Active (2.3 yrs remaining)
+1377d PTA
Expires: 2029-03-24
|
|
|
US8058291
Methods and compositions for the treatment of CNS-related conditions
|
Filed: 2006-04-06
Issued: 2011-11-15
|
Active (3.0 yrs remaining)
+1339d PTA
Expires: 2029-12-05
|
|
|
US8168209
Method and composition for administering an NMDA receptor antagonist to a subject
|
Filed: 2009-07-30
Issued: 2012-05-01
|
Expired (Term Ended)
Expires: 2026-07-18
|
|
|
US8173708
Method and composition for administering an NMDA receptor antagonist to a subject
|
Filed: 2010-04-09
Issued: 2012-05-08
|
Expired (Term Ended)
Expires: 2025-12-02
|
|
|
US8283379
Methods and compositions for the treatment of CNS-related conditions
|
Filed: 2010-04-09
Issued: 2012-10-09
|
Expired (Term Ended)
Expires: 2026-05-28
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+1377 days) / Cellect Scrutiny — Over 1377 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
18
Dispositive
0
Granted
1
Denied
1
Pending / Review
16
Motions by Category
Key Dispositive Motions & Rulings